A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

• Status: Terminated
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OPKO Health, Inc.; Transition Therapeutics Ireland Limited
• Collaborator: Elan Pharmaceuticals
• Treatments: Inositol

Criteria

Inclusion Criteria:

• Complete Week 12 visit of AG201

• Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests

Exclusion Criteria:

• Is currently using any other investigational or experimental drugs or devices

• Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study